441 related articles for article (PubMed ID: 15115406)
21. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
[TBL] [Abstract][Full Text] [Related]
22. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination.
Marais R; Spooner RA; Light Y; Martin J; Springer CJ
Cancer Res; 1996 Oct; 56(20):4735-42. PubMed ID: 8840992
[TBL] [Abstract][Full Text] [Related]
23. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.
Blakey DC; Burke PJ; Davies DH; Dowell RI; East SJ; Eckersley KP; Fitton JE; McDaid J; Melton RG; Niculescu-Duvaz IA; Pinder PE; Sharma SK; Wright AF; Springer CJ
Cancer Res; 1996 Jul; 56(14):3287-92. PubMed ID: 8764123
[TBL] [Abstract][Full Text] [Related]
24. Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT).
Monks NR; Calvete JA; Curtin NJ; Blakey DC; East SJ; Newell DR
Br J Cancer; 2000 Jul; 83(2):267-9. PubMed ID: 10901381
[TBL] [Abstract][Full Text] [Related]
25. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
Springer CJ; Niculescu-Duvaz I
Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
[TBL] [Abstract][Full Text] [Related]
26. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.
Eccles SA; Court WJ; Box GA; Dean CJ; Melton RG; Springer CJ
Cancer Res; 1994 Oct; 54(19):5171-7. PubMed ID: 7923136
[TBL] [Abstract][Full Text] [Related]
27. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage.
Kapuriya N; Kapuriya K; Zhang X; Chou TC; Kakadiya R; Wu YT; Tsai TH; Chen YT; Lee TC; Shah A; Naliapara Y; Su TL
Bioorg Med Chem; 2008 May; 16(10):5413-23. PubMed ID: 18450456
[TBL] [Abstract][Full Text] [Related]
29. Radiosynthesis of 4-[(2-chloroethyl)(2-[(11)C]ethyl)amino]-phenoxycarbonyl-l-glutamic acid a half mustard prodrug as a potential probe for imaging antibody- and gene-directed enzyme prodrug therapy with positron emission tomography.
Malik N; Luthra SK; Burke P; Price PM; Aboagye EO; Latigo J; Zhao Y; Brady F
Appl Radiat Isot; 2004 Jun; 60(6):825-34. PubMed ID: 15110346
[TBL] [Abstract][Full Text] [Related]
30. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
Napier MP; Sharma SK; Springer CJ; Bagshawe KD; Green AJ; Martin J; Stribbling SM; Cushen N; O'Malley D; Begent RH
Clin Cancer Res; 2000 Mar; 6(3):765-72. PubMed ID: 10741695
[TBL] [Abstract][Full Text] [Related]
31. Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue.
Monks NR; Blakey DC; Curtin NJ; East SJ; Heuze A; Newell DR
Br J Cancer; 2001 Sep; 85(5):764-71. PubMed ID: 11531265
[TBL] [Abstract][Full Text] [Related]
32. Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane.
Cowen RL; Williams JC; Emery S; Blakey D; Darling JL; Lowenstein PR; Castro MG
Cancer Gene Ther; 2002 Nov; 9(11):897-907. PubMed ID: 12386828
[TBL] [Abstract][Full Text] [Related]
33. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
[TBL] [Abstract][Full Text] [Related]
35. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.
Springer CJ; Antoniw P; Bagshawe KD; Searle F; Bisset GM; Jarman M
J Med Chem; 1990 Feb; 33(2):677-81. PubMed ID: 2299634
[TBL] [Abstract][Full Text] [Related]
36. Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT).
Springer CJ; Bavetsias V; Jackman AL; Boyle FT; Marshall D; Pedley RB; Bisset GM
Anticancer Drug Des; 1996 Dec; 11(8):625-36. PubMed ID: 9022750
[TBL] [Abstract][Full Text] [Related]
37. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH
Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666
[TBL] [Abstract][Full Text] [Related]
38. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy.
Friedlos F; Denny WA; Palmer BD; Springer CJ
J Med Chem; 1997 Apr; 40(8):1270-5. PubMed ID: 9111301
[TBL] [Abstract][Full Text] [Related]
39. A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs.
Spooner RA; Friedlos F; Maycroft K; Stribbling SM; Roussel J; Brueggen J; Stolz B; O'Reilly T; Wood J; Matter A; Marais R; Springer CJ
Br J Cancer; 2003 May; 88(10):1622-30. PubMed ID: 12771932
[TBL] [Abstract][Full Text] [Related]
40. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
Jain M; Fan J; Baturay NZ; Kwon CH
J Med Chem; 2004 Jul; 47(15):3843-52. PubMed ID: 15239662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]